Treatment Technology by Cedars-Sinai and Aytu Biosciences, Inc.
The proposal is to use Healight in the treatment of COVID-19.
Dr. Mark Pimentel is the lead of the Healight team.
The research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending Healight platform since 2016 and has produced a growing body of scientific evidence demonstrating pre-clinical safety and effectiveness of the technology as an antiviral and antibacterial treatment.
The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology’s significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus.
The data have been the basis of discussions with the FDA for a near-term path to enable human use for the potential treatment of coronavirus in intubated patients in the intensive care unit (ICU).
Beyond the initial pursuit of a coronavirus ICU indication, additional data suggest broader clinical applications for the technology across a range of viral and bacterial pathogens. This includes bacteria implicated in ventilator associated pneumonia (VAP).
“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” stated Dr. Pimentel of Cedars-Sinai.
Ali Rezaie, MD, one of the inventors of this technology states, “Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world.”
The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have been filed by Cedars-Sinai Department of Technology Transfer, and Aytu BioScience will manage all aspects of intellectual property prosecution and filing globally. Aytu BioScience expects to partner the product outside the U.S.
“We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond,” said Josh Disbrow, Chairman and CEO of Aytu BioScience.
The Company is engaging with the research team at Cedars-Sinai and the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.
Disbrow continued, “This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans.”
- Aytu BioScience Inc.on October 22, 2020 at 5:00 pm
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
- Aytu BioScience Announces Fiscal Q4 2020 Net...on October 8, 2020 at 5:44 pm
Aytu has also licensed the Healight™ Platform Technology. Healight is a pre-clinical investigational device being studied as a potential treatment for COVID-19 in severely ill, intubated patients and ...
- Aytu BioScience, Inc.: Aytu BioScience Announces...on October 6, 2020 at 3:08 pm
Commenting on the fourth quarter of fiscal 2020, Josh Disbrow, Chief Executive Officer of Aytu BioScience ... the addition of the Healight opportunity for COVID-19 and future potential non ...
- Aytu BioScience Announces Fiscal Q4 2020 Net...on October 6, 2020 at 3:07 pm
Aytu has also licensed the Healight™ Platform Technology. Healight is a pre-clinical investigational device being studied as a potential treatment for COVID-19 in severely ill, intubated ...
- Aytu BioScience EPS beats by $0.01, beats on...on October 6, 2020 at 1:07 pm
Aytu BioScience (NASDAQ ... equivalents and restricted cash on the balance sheet, the addition of the Healight opportunity for COVID-19 and future potential non-COVID-19 applications, and our ...
- Aytu BioScience Announces Fiscal Q4 2020 Net...on October 6, 2020 at 1:02 pm
Before it's here, it's on the Bloomberg Terminal.
- Aytu BioScience, Inc. Common Stock (AYTU)on October 5, 2020 at 5:00 pm
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
- Theralase Technologies Inc. TLTFFon October 1, 2020 at 3:33 pm
Aytu BioScience, Inc. has partnered with Cedars-Sinai to develop and commercialize its Healight Platform Technology, commonly known as “Healight”. The Healight technology delivers intermittent ...